loading
전일 마감가:
$1.79
열려 있는:
$1.82
하루 거래량:
415.40K
Relative Volume:
0.64
시가총액:
$48.63M
수익:
-
순이익/손실:
$-21.24M
주가수익비율:
-2.1721
EPS:
-0.8379
순현금흐름:
$-22.47M
1주 성능:
+26.83%
1개월 성능:
-22.88%
6개월 성능:
-63.82%
1년 성능:
-85.84%
1일 변동 폭
Value
$1.75
$1.92
1주일 범위
Value
$1.36
$1.92
52주 변동 폭
Value
$1.14
$13.51

Skye Bioscience Inc Stock (SKYE) Company Profile

Name
명칭
Skye Bioscience Inc
Name
전화
(858) 410-0266
Name
주소
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Name
직원
16
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
SKYE's Discussions on Twitter

SKYE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
 icon
SKYE
Skye Bioscience Inc.
3.10 12.89M 0 0 0 0.00
 icon
MOBBW
Mobilicom Limited Warrants
0.255 398.00M 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
19.99 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1685 343.35M 2.07B -1.42B -1.37B -0.6765
 icon
JUNE
Dhandho Junoon Etf
10.76 215.97M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
3.64 126.17M 0 0 0 0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-28 개시 William Blair Outperform
2024-09-30 개시 Scotiabank Sector Outperform
2024-09-10 개시 JMP Securities Mkt Outperform
2024-07-09 개시 Craig Hallum Buy
2024-05-23 개시 Cantor Fitzgerald Overweight
2024-04-12 개시 Oppenheimer Outperform
모두보기

Skye Bioscience Inc 주식(SKYE)의 최신 뉴스

pulisher
08:06 AM

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

08:06 AM
pulisher
Apr 23, 2025

Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat

Apr 22, 2025
pulisher
Apr 22, 2025

(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com

Apr 22, 2025
pulisher
Apr 21, 2025

SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com

Apr 21, 2025
pulisher
Apr 19, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

William Blair Predicts Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha

Apr 16, 2025
pulisher
Apr 15, 2025

Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World

Apr 11, 2025
pulisher
Apr 08, 2025

Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 28, 2025
pulisher
Mar 25, 2025

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World

Mar 23, 2025

Skye Bioscience Inc (SKYE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):